Evidence map›Paper›PMID 40045027›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Potential role of thymoquinone to treat gastrointestinal cancers: insights into its molecular mechanisms.

Tina Rahjoo, Alireza Motamedzadeh, Felora Ferdosi, Ehsan Dadgostar, Michael Aschner, Hamed Mirzaei, Sina Ghesmatpour, Fatemeh Nabavizadeh, Fatemeh Rahmati-Dehkordi, Omid Reza Tamtaji

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tina RahjooElectrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
Alireza MotamedzadehDepartment of Internal Medicine, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Felora FerdosiDepartment of Radiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Ehsan DadgostarBehavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran.
Michael AschnerDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
Hamed MirzaeiResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran.
Sina GhesmatpourElectrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
Fatemeh NabavizadehElectrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. Nabavizadeh@tums.ac.ir.
Fatemeh Rahmati-DehkordiStudents' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran. f.rahmatidehkordi.frd@gmail.com.
Omid Reza TamtajiElectrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. or-tamtaji@razi.tums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal (GI) malignancies, including esophageal cancer, gastric cancer, and colon cancer, are associated with high mortality rates worldwide. Thymoquinone is one of the main bioactive components of Nigella sativa, and it has been documented to have anticancer effects including GI cancer. Thymoquinone inhibits GI cancer progression by inducing cell cycle arrest, apoptosis, and oxidative stress and inhibiting inflammation, migration, invasion, metastasis, histone deacetylases, STAT3, PI3K/AKT/mTOR, and Wnt/β-catenin signaling pathways. Although the beneficial effects of thymoquinone have been documented, some limitations, including poor bioavailability and hydrophobicity, have hindered its clinical application. Nanotechnology approaches bypass these limitations. In this review article, we outline the different cellular and molecular pathways influenced by thymoquinone and its nanoformulations in GI cancer.

Indexed as

Antineoplastic AgentsBenzoquinonesGastrointestinal NeoplasmsAnimalsAnti-Inflammatory AgentsApoptosisCell Cycle CheckpointsHumansNigella sativaAnti-Inflammatory AgentsAntineoplastic AgentsBenzoquinonesthymoquinoneApoptosisGastrointestinal neoplasmsMetastasisNanotechnologyThymoquinone

Identifiers

PMID40045027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.